Novel Dual-cell Therapy Results in Pancreatic Cancer
Filed with ASX · · 8 pages · English
Earlier from Noxopharm
- Response to ASX Price Query
- June 2022 Quarterly Activities Report and Appendix 4C
- March 2022 Quarterly Activities Report and Appendix 4C
- FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
- Orphan Drug Designation Granted to Noxopharm by US FDA
Later from Noxopharm
- September 2022 Quarterly Activities Report and Appendix 4C
- NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
- DARRT-2 Trial Efficacy Phase to Commence
- December 2022 Quarterly Activities Report and Appendix 4C
- Appendix 4D and Half Year 2023 Financial Report
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm